ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,579.80 ▲ 19.00 (1.22%)ENR.DE: $160.76 ▼ -1.74 (-1.07%)GLEN.L: $531.80 ▼ -3.50 (-0.65%)IFX.DE: $81.47 ▲ 0.91 (1.13%)NOKIA.HE: $12.38 ▲ 0.38 (3.17%)RIO.L: $7,259.00 ▼ -5.00 (-0.07%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Agile Therapeutics, Inc.

AGRX - NASDAQ

Identifiants & Marche

Ticker AGRX
ISIN US00847L3087
CIK 0001261249
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.